탈장 교정 기기 및 수술 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the hernia repair devices and procedures market size was valued at USD 6.77 billion in 2025 and estimated to grow from USD 7.06 billion in 2026 to reach USD 8.71 billion by 2031, at a CAGR of 4.29% during the forecast period (2026-2031).

This report is Segmented by Product (Polypropylene/Composite Synthetic Mesh, and More), Procedure (Open Tension Repair, and More), Hernia Type (Inguinal Hernia, and More), Material (Synthetic, and More), End User (Hospitals, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Hernia Repair Devices And Procedures Market Trends and Insights

Rising Global Surgical Hernia Burden

Worldwide hernia incidence is climbing, with analysts projecting a 19.7% increase in new cases by 2050 as populations age and obesity rates rise. Adults older than 45 now account for most new diagnoses, and a male-to-female ratio of roughly 7:1 concentrates demand among men. In low- and middle-income nations such as India and China, procedural backlogs persist, positioning these regions as sizeable untapped volumes once surgical capacity expands. The sheer epidemiologic weight supplies the hernia repair devices and procedures market with steady baseline growth.

Advancements In Minimally Invasive Repair Technologies

Robotic systems and improved laparoscopic instrumentation deliver smaller incisions, less postoperative pain and faster return to work. Real-world data showed median console times of 37 minutes for unilateral robotic repairs and quick learning curves among early adopters. Although capital expense remains high, payer coverage is broadening and AI-guided planning is expected to shorten training cycles. Premium mesh designs compatible with robotic delivery also command higher average selling prices, supporting revenue gains even where case volumes plateau.

High Cost Of Biologic And Biosynthetic Meshes

Biologic patches derived from porcine dermis or bovine pericardium can cost 5-10 times more than polypropylene, limiting uptake where payer budgets are tighter. Even biosynthetics such as Gore BIO-A run well above heavyweight mesh, and extended operating-room time adds further expense. Hospitals in emerging markets therefore default to suture-only or basic polypropylene techniques, tempering global adoption curves.

Other drivers and restraints analyzed in the detailed report include:

1. Expanding Insurance Coverage For Elective Hernia Surgeries
2. Growing Adoption Of Composite And Lightweight Meshes
3. Product Recalls And Litigation Over Mesh Complications

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Synthetic polypropylene commanded 47.92% of revenue in 2025, underscoring its entrenched clinical track record and budget-friendly pricing. The hernia repair devices and procedures market size for synthetic mesh equated to nearly half of total industry sales last year. Lightweight, large-pore designs are helping retain share by reducing postoperative pain. Biologic and biosynthetic alternatives hold smaller volume now but are climbing at 6.23% CAGR as infection-prone ventral cases drive surgeons toward absorbable or hybrid constructs.

The fixation sub-segment is modernising as well. TELA Bio's LIQUIFIX, the first FDA-cleared liquid adhesive for internal hernia use, is gaining traction for its uniform distribution and reduced tack trauma. Antimicrobial coatings, especially chlorhexidine films, are also differentiating suppliers by cutting infection risk versus gentamicin-impregnated competitors. Suppliers that marry mesh, fixation and adjunct tools into single-vendor kits strengthen their stickiness with purchasing committees.

Open tension-free Lichtenstein still represented 42.10% of 2025 procedures, a testament to surgeon familiarity and low consumable cost. For many straightforward inguinal cases, hospitals retain this approach to maximise throughput and minimise capital spend. Yet robotic-assisted laparoscopic repair is advancing at 6.55% CAGR, winning converts for complex bilateral and ventral presentations where ergonomics and 3-D visualisation pay off.

The hernia repair devices and procedures market share for robotic systems continues to rise as ASC investment grows and vendors roll out lower-priced four-arm models. Early recurrence spikes reported in Nordic registries appear tied to learning curves rather than intrinsic technique flaws. AI-enhanced vision is expected to flatten that curve, broadening the surgeon pool and lifting disposable instrument volumes.

Complete Report Scope:

• By Product
  • Synthetic Polypropylene Mesh
  • Expanded-PTFE Mesh
  • Light-Weight Large-Pore Mesh
  • Biologic/Biosynthetic Mesh
  • Surgical & Endoscopic Instruments
  • Fixation Devices (Tackers, Sutures, Glues)
• By Procedure
  • Open Tension Repair
  • Open Tension-Free (Lichtenstein) Repair
  • Laparoscopic Intraperitoneal-Onlay Mesh (IPOM)
  • Robotic-Assisted Laparoscopic Repair
• By Hernia Type
  • Inguinal Hernia
  • Incisional/Ventral Hernia
  • Umbilical Hernia
  • Femoral & Other Hernias
• By Material
  • Synthetic
  • Biologic
  • Hybrid Biosynthetic
• By End User
  • Hospitals
  • Ambulatory Surgical Centres (ASCs)
  • Specialty Hernia Clinics
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 39.98% of global revenue in 2025, supported by high procedure volumes, early technology uptake and broad insurance coverage. Medicare alone reimburses more than 1 million hernia repairs annually, translating to a USD 2.5 billion addressable spend for meshes, fixation and instruments. U.S. robotic penetration in inguinal repair hit 24.2% by 2019, and the FDA's new labelling guidance is expected to standardise performance claims, smoothing future rollouts. Canada and Mexico add incremental growth through cross-border medical tourism and infrastructure upgrades.

Europe trails slightly but benefits from robust clinical registries that favour premium devices with long-term data. Germany, the United Kingdom and France are early adopters of lightweight and biosynthetic meshes, while Southern Europe is raising laparoscopic and robotic volumes to cut LOS and chronic pain. The 2025 European launch of TELA Bio's OviTex Inguinal underpins distributor interest in solutions optimised for minimally invasive and robotic delivery. Nonetheless, reimbursement heterogeneity across 27 EU states requires suppliers to tailor value dossiers country by country.

Asia-Pacific is the fastest-growing geography, advancing at 5.59% CAGR through 2031. China and India each conduct more than 1 million repairs yearly, yet mesh usage remains uneven, creating white-space for economical synthetics and mid-tier biosynthetics. Japan's mature payer system supports robotic adoption, while Australia and South Korea champion outpatient pathways. International OEMs increasingly partner with regional distributors to navigate varying regulatory timelines and local tender processes.

1. Medtronic
2. Johnson & Johnson
3. Beckton Dickinson
4. B. Braun
5. W. L. Gore & Associates
6. Cook Group
7. Olympus
8. The Cooper Companies
9. Insightra Medical
10. Abbvie
11. Atrium Maquet (Getinge)
12. Integra Lifesciences (LifeCell)
13. C. R. Bard (BD Subsidiary)
14. Herniamesh S.r.l.
15. Cousin Biotech
16. Novus Scientific
17. Tepha Inc.
18. Baxter
19. Advanced Medical Solutions
20. Lepu Medical
21. Shanghai Puwei Medical
22. Dynamesh

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Global Surgical Hernia Burden
  • 4.2.2 Advancements In Minimally Invasive Repair Technologies
  • 4.2.3 Expanding Insurance Coverage For Elective Hernia Surgeries
  • 4.2.4 Growing Adoption of Composite and Lightweight Meshes
  • 4.2.5 Surge In Ambulatory Surgery Center Procedures
  • 4.2.6 Integration of Robotics and AI For Enhanced Surgical Outcomes
• 4.3 Market Restraints
  • 4.3.1 High Cost of Biologic and Biosynthetic Meshes
  • 4.3.2 Product Recalls and Litigation Over Mesh Complications
  • 4.3.3 Shortage of Skilled Laparoscopic and Robotic Surgeons
  • 4.3.4 Procurement Delays Due to Capital Budget Constraints in Hospitals
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat Of New Entrants
  • 4.5.2 Bargaining Power Of Buyers
  • 4.5.3 Bargaining Power Of Suppliers
  • 4.5.4 Threat Of Substitutes
  • 4.5.5 Intensity Of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Synthetic Polypropylene Mesh
  • 5.1.2 Expanded-PTFE Mesh
  • 5.1.3 Light-Weight Large-Pore Mesh
  • 5.1.4 Biologic/Biosynthetic Mesh
  • 5.1.5 Surgical & Endoscopic Instruments
  • 5.1.6 Fixation Devices (Tackers, Sutures, Glues)
• 5.2 By Procedure
  • 5.2.1 Open Tension Repair
  • 5.2.2 Open Tension-Free (Lichtenstein) Repair
  • 5.2.3 Laparoscopic Intraperitoneal-Onlay Mesh (IPOM)
  • 5.2.4 Robotic-Assisted Laparoscopic Repair
• 5.3 By Hernia Type
  • 5.3.1 Inguinal Hernia
  • 5.3.2 Incisional/Ventral Hernia
  • 5.3.3 Umbilical Hernia
  • 5.3.4 Femoral & Other Hernias
• 5.4 By Material
  • 5.4.1 Synthetic
  • 5.4.2 Biologic
  • 5.4.3 Hybrid Biosynthetic
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Ambulatory Surgical Centres (ASCs)
  • 5.5.3 Specialty Hernia Clinics
• 5.6 Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East & Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 Medtronic Plc
  • 6.3.2 Johnson & Johnson (Ethicon)
  • 6.3.3 Becton, Dickinson and Company
  • 6.3.4 B. Braun SE
  • 6.3.5 W. L. Gore & Associates
  • 6.3.6 Cook Medical LLC
  • 6.3.7 Olympus Corporation
  • 6.3.8 CooperSurgical Inc.
  • 6.3.9 Insightra Medical
  • 6.3.10 AbbVie Inc. (Allergan)
  • 6.3.11 Atrium Maquet (Getinge)
  • 6.3.12 Integra Lifesciences (LifeCell)
  • 6.3.13 C. R. Bard (BD Subsidiary)
  • 6.3.14 Herniamesh S.r.l.
  • 6.3.15 Cousin Biotech
  • 6.3.16 Novus Scientific
  • 6.3.17 Tepha Inc.
  • 6.3.18 Baxter International
  • 6.3.19 Advanced Medical Solutions
  • 6.3.20 Lepu Medical
  • 6.3.21 Shanghai Puwei Medical
  • 6.3.22 Dynamesh

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment